阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

休市中 11-06 16:00:00 EST

186.43

-0.42

-0.22%

盘后185.92

-0.51-0.27%

19:59 EST

最高187.33	最低181.20	成交量284.71万
今开181.34	昨收186.85	日振幅3.28%
总市值2,892亿	流通市值2,794亿	总股本15.51亿
成交额5.27亿	换手率0.19%	流通股本14.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":186.43,"timestamp":1793998800000,"preClose":186.85,"halted":0,"volume":2847055,"hourTrading":{"tag":"盘后","latestPrice":185.92,"preClose":186.43,"latestTime":"19:59 EST","volume":271022,"amount":50527252.0787,"timestamp":1794013188123,"change":-0.51,"changeRate":-0.002736,"amplitude":0.011157},"delay":0,"changeRate":-0.002247792346802181,"floatShares":1498932637,"shares":1551000000,"eps":7.059667,"marketStatus":"休市中","change":-0.42,"latestTime":"11-06 16:00:00 EST","open":181.34,"high":187.33,"low":181.2035,"amount":527476100.5529,"amplitude":0.032788,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.059667,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":186.85,"dividendRate":0.017235,"preHourTrading":{"tag":"盘前","latestPrice":181.31,"preClose":186.85,"latestTime":"09:29 EST","volume":42308,"amount":7668313.57684,"timestamp":1793975399999,"change":-5.54,"changeRate":-0.029649,"amplitude":0.013754},"postHourTrading":{"tag":"盘后","latestPrice":185.92,"preClose":186.43,"latestTime":"19:59 EST","volume":271022,"amount":50527252.0787,"timestamp":1794013188123,"change":-0.51,"changeRate":-0.002736,"amplitude":0.011157},"volumeRatio":0.6636923460743634,"impliedVol":0.2829,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2681381039","title":"共筑筛诊治管全链路，阿斯利康携手各方同创癌症防治新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2681381039","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681381039?lang=zh_cn&edition=full","pubTime":"2026-11-07 17:00","pubTimestamp":1794042000,"startTime":"0","endTime":"0","summary":"本届进博会上，阿斯利康与和誉医药、赛岚医药两家中国本土医药企业签署合作备忘录，携手开展肺癌领域联合治疗的研究探索。近年来，阿斯利康持续携手本土合作伙伴，推进联合治疗研究探索，已与10家企业达成14项深度合作。关于阿斯利康中国 中国是阿斯利康全球第二大市场，也是其全球创新的战略枢纽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"https://www.prnasia.com/story/archive/5091946_ZH91946_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnasia.com/story/archive/5091946_ZH91946_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1829250122.USD","AZNH","LU2468319806.SGD","LU2089984988.USD","BK4588","LU2236285917.USD","LU2456880835.USD","LU0058720904.USD","LU2237443622.USD","LU2237443549.SGD","LU2417539215.USD","LU0128525929.USD","LU0889565916.HKD","LU2462157665.USD","IBBQ","LU2237443382.USD","LU2237443895.HKD","LU0289739699.SGD","LU2237443465.HKD","LU0708994859.HKD","LU0320765992.SGD","BK4007","LU0310800379.SGD","IE00B3T34201.USD","BK4568","LU0432979614.USD","LU0109394709.USD","LU0029864427.USD","LU2237443978.SGD","AZN","LU1267930573.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142658260","title":"异动解读｜阿斯利康盘前下跌3.01%，市场权衡百亿美元收购Rhythm传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=1142658260","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142658260?lang=zh_cn&edition=full","pubTime":"2026-11-06 18:17","pubTimestamp":1793960226,"startTime":"0","endTime":"0","summary":"11月6日，阿斯利康盘前下跌3.01%，报181.21美元/股，成交额51.09万美元。消息面上，市场仍在消化其拟以约100亿美元收购Rhythm Pharmaceuticals的传闻。披露信息显示，相关报价约为每股124美元，另有说法称最高可达每股134美元并包含里程碑付款；若推进，交易或通过阿斯利康罕见病业务Alexion进行，以补强罕见病与肥胖症产品布局。阿斯利康近期基本面并不弱，上一季度非GAAP每股收益2.79美元、营收162.1亿美元，且肿瘤业务销售额同比增长17%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"阿斯利康大跌，百亿美元收购传闻引发担忧","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681062700","title":"据华尔街日报：据知情人士透露，阿斯利康(AZN.O)向Rhythm Pharmaceuticals提出了100亿美元的收","url":"https://stock-news.laohu8.com/highlight/detail?id=2681062700","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681062700?lang=zh_cn&edition=full","pubTime":"2026-11-05 05:02","pubTimestamp":1793826134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2462157665.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU2237443978.SGD","LU0708994859.HKD","BK4568","LU0029864427.USD","LU0058720904.USD","LU0432979614.USD","BK4588","LU1829250122.USD","LU2236285917.USD","LU2089984988.USD","BK4585","LU2417539215.USD","LU1267930573.SGD","LU2237443465.HKD","AZN","LU0310800379.SGD","LU0320765992.SGD","LU2468319806.SGD","BK4007","LU2456880835.USD","LU0289739699.SGD","LU0109394709.USD","LU2237443549.SGD","LU0128525929.USD","LU2237443382.USD","LU2237443895.HKD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188961921","title":"异动解读｜阿斯利康盘中上涨3.06%，投行上调目标价强化市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1188961921","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188961921?lang=zh_cn&edition=full","pubTime":"2026-11-05 00:40","pubTimestamp":1793810446,"startTime":"0","endTime":"0","summary":"11月5日，阿斯利康盘中上涨3.06%，报189.46美元，成交额3.35亿美元。最新催化来自机构观点上修，加拿大皇家银行将阿斯利康目标价由145英镑上调至152.50英镑，维持跑赢大盘评级。叠加此前公司三季度业绩超预期，核心每股收益2.79美元，高于市场预期的2.60美元，营收162.1亿美元，同比增长7%，其中肿瘤业务销售额增长17%，近期欧日监管部门亦受理Orpathys与Tagrisso联合疗法申报，继续支撑其中长期产品线预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康获投行上调目标价，盘中走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178757986","title":"美股异动｜美股医药股续涨，阿斯利康绩后涨超6%；美股半导体股、存储股、光通信股重挫，英特尔暴跌29%，闪迪跌9%，迈威尔跌7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178757986","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178757986?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:46","pubTimestamp":1793367995,"startTime":"0","endTime":"0","summary":"美股医药股续涨，阿斯利康绩后涨超6%，Q3利润超预期；礼来、吉利德科学涨超4%，安进涨近3%，强生涨近2%，盘中股价均创历史新高。美股半导体股重挫，英特尔暴跌 29%，迈威尔跌 7%，超微电脑 5%。存储股大跌，闪迪跌 9%，西部数据、希捷科技跌 5%。美股光通信板块普跌，Lumentum跌8%，康宁跌2%，Coherent跌9%。","market":"us","thumbnail":"https://static.tigerbbs.com/aab667b22ddd84f63ad2db656e8a0d4f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/aab667b22ddd84f63ad2db656e8a0d4f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTW","LINT","SNXX","INT","AZN","SNDC","SNDQ","INTC","INYY","SNDG","SNDK","SNDU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104546723","title":"异动解读｜阿斯利康盘中上涨5.75%，三季度业绩超预期且重申全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1104546723","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104546723?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:38","pubTimestamp":1793367533,"startTime":"0","endTime":"0","summary":"10月30日，阿斯利康盘中上涨5.75%，报186.1美元/股，成交额1.12亿美元。消息面上，公司第三季度业绩超出市场预期，并重申全年业绩指引，提振市场情绪。数据显示，阿斯利康第三季度非GAAP每股收益2.79美元，高于市场预期的2.62美元；营收162.1亿美元，同比增长7%，较预期高出2.1亿美元。其中肿瘤业务销售额同比增长17%，成为核心增长引擎；公司同时维持全年收入中高个位数增长、核心每股收益低两位数增长预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康业绩超预期，盘中大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679292239","title":"阿斯利康（AZN）三季度非GAAP每股收益2.79美元超预期 营收同比增长7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679292239","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679292239?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:23","pubTimestamp":1793355791,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康 公布2026年第三季度财报，数据显示，公司当季非GAAP每股收益达2.79美元，按固定汇率计算增长19%，高于市场预期的2.62美元。期内，阿斯利康营收同比增长7%至162.1亿美元，较预期多2.1亿美元。其中，肿瘤业务部门表现最为亮眼，销售额同比大增17%。业绩指引方面，阿斯利康重申2026全年业绩指引，预计按固定汇率计算的总收入将实现中高个位数增长，核心每股收益将实现低两位数增长。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MjdiYzQwMTAxNzg2ODk4MjI3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjdiYzQwMTAxNzg2ODk4MjI3.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307811","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UDN","UUP","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139921529","title":"异动解读｜阿斯利康盘前上涨3.16%，Enhertu获欧盟批准拓展早期乳腺癌适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1139921529","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139921529?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:04","pubTimestamp":1793347447,"startTime":"0","endTime":"0","summary":"10月30日，阿斯利康盘前上涨3.16%，报180.74美元/股，成交额110.44万美元。消息面上，欧盟委员会近日批准阿斯利康与第一三共联合开发的Enhertu，用于早期乳腺癌辅助治疗，强化了公司肿瘤管线商业化预期。此次批准基于三期试验结果，Enhertu较T-DM1将浸润性疾病复发或死亡风险降低53%，三年无浸润性疾病生存率为92.4%，而对照组为83.7%；该事件同时触发阿斯利康向第一三共支付7500万美元里程碑款，显示产品推进已进入更实质的商业兑现阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679002267","title":"阿斯利康Q3利润增幅超预期，肿瘤药物为增长主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2679002267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679002267?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:58","pubTimestamp":1793347130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康10月30日发布2026年第三季度业绩。罕见病业务增长10%，呼吸与免疫增长11%。前九个月营收468.81亿美元，CER增长7%;核心EPS 8.00美元，增长14%。在首席执行官苏博科领导下，阿斯利康正寻求通过联合用药扩大其抗癌药物的适用范围。阿斯利康还展示，泰瑞沙与另一款肿瘤药物联合使用，在另一种肺癌中延缓了疾病进展。年初以来，阿斯利康股价已下跌5.4%。包括老牌抗凝血药倍林达在内的部分心血管药物上季度销售额出现下滑。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516000.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康Q3利润增幅超预期，肿瘤药物为增长主力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UDN","UUP","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118795944","title":"异动解读｜阿斯利康盘中上涨3.06%，欧盟批准Enhertu拓展早期乳腺癌适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1118795944","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118795944?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:43","pubTimestamp":1793281412,"startTime":"0","endTime":"0","summary":"10月29日，阿斯利康盘中上涨3.06%，报174.56美元/股，成交额5743.01万美元。消息面上，欧盟委员会近日批准阿斯利康与第一三共联合开发的Enhertu，用于早期乳腺癌辅助治疗，强化了公司肿瘤管线商业化预期。该批准基于三期试验结果，Enhertu较T-DM1将浸润性疾病复发或死亡风险降低53%，三年无浸润性疾病生存率为92.4%；同时该事件将触发阿斯利康向第一三共支付7500万美元里程碑款。临近业绩披露前，市场原本已预期公司季度营收同比增长8.52%，肿瘤业务持续放量成为关注重点。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康盘中上涨，欧盟批准Enhertu拓展新适应症","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678935411","title":"CLARITY-Gastric01 试验显示，Sone-Ve治疗二线及后线的 CLDN18.2 表达的晚期胃癌/胃食管结合部癌患者可降低死亡风险达 42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678935411","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678935411?lang=zh_cn&edition=full","pubTime":"2026-10-26 19:06","pubTimestamp":1793012760,"startTime":"0","endTime":"0","summary":"Sone-Ve在主要终点中使三线及以后治疗患者的死亡风险降低 53%。作为首个在该治疗人群中显示生存获益的CLDN18.2靶向疗法，Sone-Ve相比于对照组，将中位生存期延长了四个多月，有望改变CLDN18.2表达患者的治疗格局。关于胃癌与胃食管结合部癌 胃癌是全球第五大常见癌症，也是第五大癌症相关死亡原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5080677_ZH80677_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5080677_ZH80677_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IBBQ","BPI","BTC","BTCL","BITY","ADC","CBOA","EAC","CBOO","AZN","GBTC","CBTJ","BTF","CBOY","CBXO","COAL","CBOJ","AZNH","SBIT","DFII","BTCO","MAXI","BTCZ","BRRR","CBTA","CBXA","HCC","NETL","BAGY","BITU","HODL","BITB","BCCC","TRAE","CBTO","CBXY","EZBC","PFS","YBTC","XBTY","CBXJ","BTRN","CBTY","DEFI","BETH","BTCC","MNRS","BITO","FBTC","BTCW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678643331","title":"DeLLphi-305 Ⅲ期临床试验结果显示：英飞凡联合安泰适一线治疗广泛期小细胞肺癌，将死亡风险降低58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678643331","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678643331?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:47","pubTimestamp":1793008020,"startTime":"0","endTime":"0","summary":"联合治疗组约有79%的患者在一年时仍存活，而单药组这一比例为53%。联合治疗组的中位PFS为7.4个月，而单药组为1.9个月。联合方案治疗导致的治疗终止发生率较低，且未发生与治疗相关的死亡事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5080617_ZH80617_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5080617_ZH80617_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["FBT","BBH","XPH","BK4007","HELX","FTXH","GNOM","LU0889565916.HKD","RSPH","LU0708994859.HKD","SYNB","LU2322448791.USD","LU0289739699.SGD","BME","IBB","LU1992135399.USD","PBPH","IEIH","LU2272731865.HKD","MRNY","BIOY","PJP","PPH","PSCH","PBE","XBIX","IDNA","LU1992135472.HKD","LU2237443549.SGD","LU2089984988.USD","WDNA","TMED","AZNH","BIB","SBIO","BBP","RXL","IBRN","LU0128525929.USD","IE00B5TLWC47.USD","LU2237443465.HKD","LU2417539215.USD","LFSC","MEDI","AZN","LU2237443382.USD","IYH","MRNX","CANC","IEHS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133769190","title":"安进：药物联合疗法可使侵袭性肺癌患者的死亡风险降低 58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133769190","media":"老虎资讯综合","labels":["EditorSelect"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133769190?lang=zh_cn&edition=full","pubTime":"2026-10-25 07:48","pubTimestamp":1792885730,"startTime":"0","endTime":"0","summary":"要点研究发现，安进的一款药物若与阿斯利康的一种免疫疗法联合使用，可能显著延长患有一种恶性程度极高的肺癌患者的生存时间。周六公布的一项后期临床试验完整结果显示，对于广泛期小细胞肺癌患者，在阿斯利康的英飞凡药物治疗方案中加入安进的免疫疗法 Imdelltra，可将死亡风险降低 58%。安进表示，在开始同时服用这两种药物的患者中，近 80% 的患者在一年后仍然存活，而单独接受英飞凡治疗的患者这一比例为 53%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/74cb91f8da76ac573efb56eb53aab6f2","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/74cb91f8da76ac573efb56eb53aab6f2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"安进：药物联合疗法可使侵袭性肺癌患者的死亡风险降低 58%","news_tag":"EditorSelect","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","AMGN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1122363301","title":"财报前瞻 | 阿斯利康本季度营收预计增8.52%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1122363301","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122363301?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:07","pubTimestamp":1792714051,"startTime":"0","endTime":"0","summary":"阿斯利康将于2026年10月30日发布新财季业绩，市场聚焦肿瘤与免疫产品放量对收入与盈利质量的拉动。市场一致预期本季度阿斯利康营收为160.47亿美元，同比增长8.52%；调整后每股收益为2.60美元，同比增长14.27%；息税前利润为52.53亿美元，同比增长10.17%；未见明确的毛利率与净利润或净利率的市场预测披露。公司当前的主要业务亮点在于肿瘤板块，上季度实现收入73.26亿美元，同比增长15.00%，受益于核心抗肿瘤产品与ADC商业化推进。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 阿斯利康本季度营收预计增8.52%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140068025","title":"异动解读｜阿斯利康盘中上涨3.08%，两项FDA进展与新药在美上市提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1140068025","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140068025?lang=zh_cn&edition=full","pubTime":"2026-10-23 00:31","pubTimestamp":1792686663,"startTime":"0","endTime":"0","summary":"10月23日，阿斯利康盘中上涨3.08%，报173.6314美元，成交额2.39亿美元。消息面上，公司连续披露监管与商业化进展，包括Zegfrovy在美国上市，以及Ultomiris获FDA加速批准用于降低IgA肾病成人患者蛋白尿。其中，Ultomiris基于III期I CAN试验中期分析获批，34周时较安慰剂降低蛋白尿43.4%；Zegfrovy则在美国可用于特定EGFR相关局部晚期或转移性非小细胞肺癌成人患者。连续产品催化强化了公司肿瘤与罕见病管线兑现预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康股价上涨，新药获批提振信心","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183074644","title":"异动解读｜阿斯利康盘中上涨3.04%，Tezspire三期试验结果提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1183074644","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183074644?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:47","pubTimestamp":1792518424,"startTime":"0","endTime":"0","summary":"10月21日，阿斯利康盘中上涨3.04%，报168.94美元，成交额2.95亿美元。消息面上，公司与安进披露，Tezspire在治疗症状性且未受控嗜酸性粒细胞性食管炎的三期Crossing试验中，达到统计学显著且具临床意义的改善。具体看，患者在第24周组织学缓解率分别为64.8%和68.9%，显著高于安慰剂组的3.5%；吞咽困难症状评分降幅分别为18.8分和22分，也优于安慰剂组的14.7分，且疗效维持至第52周。这一进展强化了其免疫炎症管线扩适应症预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"阿斯利康异动，Tezspire三期数据提振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676656094","title":"阿斯利康(AZN.US)：与甲骨文(ORCL.US)合作的相关项目将覆盖肿瘤、心血管、肾脏代谢疾病、呼吸、免疫、罕见病等","url":"https://stock-news.laohu8.com/highlight/detail?id=2676656094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676656094?lang=zh_cn&edition=full","pubTime":"2026-10-20 12:12","pubTimestamp":1792469535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1267930573.SGD","LU0889565916.HKD","LU0029864427.USD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU1829250122.USD","LU2417539215.USD","LU0289739699.SGD","LU2237443382.USD","LU2237443622.USD","AZNH","LU0708994859.HKD","LU2237443465.HKD","BK4007","LU2237443978.SGD","LU2089984988.USD","LU0058720904.USD","LU0128525929.USD","LU2236285917.USD","BK4568","LU2462157665.USD","LU2237443549.SGD","LU2456880835.USD","LU2237443895.HKD","IE00B3T34201.USD","LU0310800379.SGD","LU0432979614.USD","LU2468319806.SGD","BK4585","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160526008","title":"美股异动｜美股药品制造商板块逆市走强，阿斯利康、施贵宝、礼来涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160526008","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160526008?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:07","pubTimestamp":1792073252,"startTime":"0","endTime":"0","summary":"美股药品制造商板块逆市走强，阿斯利康、施贵宝、礼来涨超4%，葛兰素史克、诺和诺德、诺华制药涨超3%，强生、辉瑞、默沙东、艾伯维涨超2%。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","LLYX","BMY","LLY","LLII","ELIL","ELIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168537584","title":"异动解读｜阿斯利康盘中上涨3.75%，签署AI药物发现合作强化研发预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1168537584","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168537584?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:36","pubTimestamp":1792071363,"startTime":"0","endTime":"0","summary":"10月15日，阿斯利康盘中上涨3.75%，报169.2美元，成交额6256.32万美元。消息面上，公司宣布与AI药物研发企业insitro达成药物发现与授权合作，围绕MASH及心肌病等领域推进靶点识别，提振市场对其前沿研发能力的预期。根据协议，insitro将获得4000万美元首付款，并有资格取得最高14.6亿美元开发及商业化里程碑付款，另享全球销售个位数比例特许权使用费；阿斯利康则获得相关项目在探索及早期开发后续阶段的全球独家商业化权益。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘中上涨，签AI药物合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166247508","title":"异动解读｜阿斯利康盘前上涨3.07%，签署AI药物发现合作强化研发预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166247508","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166247508?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:38","pubTimestamp":1792067916,"startTime":"0","endTime":"0","summary":"10月15日，阿斯利康盘前上涨3.07%，报166.99美元，成交额394.54万美元。消息面上，公司宣布与AI药物研发企业insitro达成药物发现与授权合作，围绕MASH及心肌病等领域利用其虚拟人AI平台识别药物靶点，强化市场对其前沿研发能力的预期。根据协议，insitro将获得4000万美元首付款，并有资格取得最高14.6亿美元开发及商业化里程碑付款，另享全球销售个位数比例特许权使用费；阿斯利康则获得相关项目在探索及早期开发后续阶段的全球独家商业化权益。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康盘前上涨，携手AI药企加速研发","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.1643},{"period":"3month","weight":0.1549},{"period":"6month","weight":0.0196},{"period":"1year","weight":0.1127},{"period":"ytd","weight":0.014}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.470588,"avgChangeRate":0.018421},{"month":7,"riseRate":0.588235,"avgChangeRate":-0.005538},{"month":8,"riseRate":0.470588,"avgChangeRate":0.003346},{"month":9,"riseRate":0.529412,"avgChangeRate":0.001076},{"month":10,"riseRate":0.558824,"avgChangeRate":0.019437},{"month":11,"riseRate":0.5,"avgChangeRate":0.003618},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}